Astral demerger plan: Chemicals spin-off in 2026

What Astral’s board approved on June 25, 2026

Astral Limited said its board has approved a composite scheme of arrangement that will reshape the group’s structure across its chemicals and plastics operations. The scheme was sanctioned at the board meeting held on June 25, 2026, under Sections 230 to 233 of the Companies Act, 2013. The reorganisation involves two parallel steps: a demerger of the chemicals business into Astral Chemie Limited and an amalgamation of Al-Aziz Plastics Private Limited into Astral Limited. Astral said the intent is to unlock value through more focused management. The company also outlined how the scheme will separate the plumbing and chemicals verticals into distinct platforms. It added that the plan is subject to statutory and regulatory clearances. Key approvals are required from the National Company Law Tribunal (NCLT), Ahmedabad Bench, SEBI, and the stock exchanges.

Demerger details: chemicals business to move to Astral Chemie

Under the scheme, Astral’s chemicals business undertaking, along with related assets and liabilities, will be transferred to Astral Chemie Limited. Astral said the transfer will be on a going concern basis. The company’s stated rationale is that a standalone chemicals entity can pursue independent capital allocation and growth strategies. Astral Chemie Limited is described as Astral’s wholly owned subsidiary in the disclosures. Post-demerger, Astral Chemie is expected to represent the chemicals vertical, while Astral Limited continues with its other operations such as plumbing. The company has not provided additional quantified segment details in the announcement beyond the chemicals turnover figure. The scheme document is also positioned as a composite arrangement, meaning the demerger and amalgamation are connected steps. Execution will depend on the sequence and timing of regulatory approvals.

Share exchange ratio: 1:1 allotment in Astral Chemie

Astral said shareholders of Astral Limited will receive one equity share of Astral Chemie Limited for every share held in Astral Limited. This 1:1 share exchange ratio is central to how value is transferred to existing shareholders. The company also stated that the shareholding pattern of Astral Chemie Limited will mirror that of Astral Limited after the scheme. Based on the disclosed split, promoters will hold 54.22% and the public will hold 45.78% in Astral Chemie Limited. The company did not indicate any change to promoter holding percentages as a result of the demerger mechanics. This structure is intended to maintain continuity for existing investors. Any listing and trading of Astral Chemie shares will depend on the completion of the scheme and listing approvals.

Al-Aziz Plastics amalgamation: no shares to be issued

Alongside the demerger, Astral said Al-Aziz Plastics Private Limited will be amalgamated into Astral Limited. The company stated that this amalgamation will result in the dissolution of the transferor company without any share issuance. Astral also noted that there will be no change in the shareholding pattern of Astral Limited following the amalgamation. In practice, this indicates the merger is being structured without diluting Astral shareholders through new equity. Astral did not share financial details for Al-Aziz Plastics in the provided text. The amalgamation is part of the same composite scheme that requires NCLT and market regulator approvals. The final legal effectiveness will be subject to the scheme being sanctioned by relevant authorities.

Listing plan: Astral Chemie shares proposed on NSE and BSE

Astral said the equity shares of Astral Chemie Limited are proposed to be listed on the National Stock Exchange of India Limited and BSE Limited. Listing is an important step because it enables price discovery and liquidity for the demerged chemicals business. The company’s statement indicates that Astral Chemie will operate as a separately listed platform after the scheme becomes effective. The proposal also aligns with the disclosed intention of allowing each vertical to pursue independent strategies. However, the company has clearly stated that approvals from SEBI and the stock exchanges are required. The exact timeline for listing was not specified in the provided material. Investors will likely track exchange observations, SEBI clearances, and the NCLT order for the final implementation schedule.

Chemicals business financial snapshot: FY26 turnover disclosed

Astral disclosed that for the year ended March 31, 2026, the chemicals business reported turnover of ₹12,663 million. Normalised to a single base unit, that equals ₹1,266.3 crore (since ₹10 million equals ₹1 crore). This is the only explicit financial metric provided for the chemicals vertical in the supplied text. The turnover disclosure helps investors size the scale of the demerged undertaking relative to the wider group. Astral did not provide segment profit, margins, or capital employed figures in the same disclosure excerpt. Any further financial separation details are expected to be part of scheme documents or subsequent filings.

DSS acquisition: 60% stake for ₹39.11 crore

Separately from the demerger scheme, Astral said its wholly owned subsidiary Astral Chemie Limited has entered into definitive agreements to acquire a 60% partnership interest in Differentiated and Sustainable Solutions LLP (DSS). The aggregate consideration for the acquisition is ₹39.11 crore. Astral said the transaction is expected to be completed on or before August 31, 2026. Upon completion, DSS will become a subsidiary of Astral Chemie and a step-down subsidiary of Astral Limited. The company positioned the deal as a move to strengthen the chemicals vertical and capture broader industrial market share, with a focus on chemicals and industrial adhesives. The disclosure confirms Astral Chemie as the acquisition vehicle for this transaction.

Analyst note: Investec reiterates Buy, target ₹1,710

Investec has maintained a Buy rating on Astral Ltd with a target price of ₹1,710. The brokerage described the DSS acquisition as a strategic move aimed at deepening backward integration in specialty chemicals. It also flagged potential benefits such as cost efficiencies and the creation of a scalable new growth vertical. At the same time, Investec noted that visibility on revenue ramp-up from DSS remains awaited. The comment suggests the strategic intent is clear, while near-term contribution is still to be evidenced. Astral’s disclosures did not provide revenue or profitability numbers for DSS in the provided text.

Market and investor engagement updates in June 2026

The provided market snapshot showed Astral Limited at ₹1,486.90 with a change of -₹49.80. Another line in the text stated the current price of Astral Ltd is ₹1,498.30. Since timestamps and contexts for these two quotes were not provided, they should be treated as separate snapshot references included in the source material.

Astral also disclosed a management investor engagement plan ahead of the restructuring announcement. The company said its management would engage with institutional investors on June 8, 2026, in Mumbai as part of the ICICI Securities India Investor Conference 2026. Astral planned one-on-one and group meetings with 38 entities. The list of participants mentioned includes SBI Life Insurance Co Ltd and ICICI Prudential Life Insurance Co Ltd. The meetings are intended to discuss business performance and strategy.

Key facts table: scheme terms, approvals, and numbers

What investors will watch next

The scheme’s progress will depend on the regulatory process, including observations from stock exchanges, SEBI review, and NCLT sanction. Astral has already specified the forum as the NCLT Ahmedabad Bench. Investors will also track filings that clarify the appointed date and the effective date, as those determine when the transfer of the chemicals undertaking legally takes place. For Astral Chemie, the proposed listing on NSE and BSE is a key milestone because it enables separate valuation for the chemicals business. Separately, the completion of the DSS transaction by August 31, 2026 is another near-term event, given Astral Chemie is the acquirer. Finally, management discussions with institutional investors provide an opportunity for the company to explain the strategic rationale and implementation steps in more detail.

Conclusion

Astral’s composite scheme approved on June 25, 2026 sets up a demerger of its chemicals business into Astral Chemie with a 1:1 share entitlement for Astral shareholders, alongside the amalgamation of Al-Aziz Plastics into Astral without share issuance. The company has disclosed FY26 chemicals turnover of ₹1,266.3 crore and said the scheme needs NCLT, SEBI, and stock exchange approvals before it becomes effective. In parallel, Astral Chemie’s planned acquisition of a 60% stake in DSS for ₹39.11 crore, expected to close by August 31, 2026, adds a separate chemicals-focused corporate action for investors to monitor.